Auriculon: The company currently has only one innovative drug project under research, the ALK-N001 project.

Englecon Announcement: The company has noticed that the market has high interest in the innovative pharmaceutical business recently. Currently, the company has only one innovative drug project in research, which is the ALK-N001 project. This project received a notification of drug clinical trial approval in April 2025 and is still in phase I clinical trials as of the disclosure date of this announcement. In addition, the company has noticed that investors are interested in the company's ALK-N002 project, which is a new innovative drug pipeline project planned to be introduced at the beginning of 2025. It has been included in the adjustment plan for the implementation of annual fundraising investment projects. As of the disclosure date of this announcement, there are multiple candidate drugs under screening and discussion for this project, and the specific pipeline has not been determined yet. Due to the fact that the indications of the candidate drugs involve commercial secrets, the company will strictly fulfill its disclosure obligations in accordance with relevant regulations in a timely manner based on the progress of the project.